Single and Multiple Dose Study to Evaluate Safety and Pharmacokinetics of BMS-986533 in Healthy Participants and Assessments of Food and pH Effects on Relative Bioavailability, and Drug-Drug Interaction Potential in Healthy Participants

Part of paid clinical trials in Lincoln, Nebraska.

Sponsor
Bristol-Myers Squibb
Study ID
NCT07629999
Phase
PHASE1
Status
Recruiting

Conditions

  • Healthy Volunteers

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • BMS-986533 — DRUG
    Specified dose on specified days
  • Famotidine — DRUG
    Specified dose on specified days
  • Placebo — DRUG
    Specified dose on specified days
  • Dabigatran Etexilate — DRUG
    Specified dose on specified days
  • Rosuvastatin — DRUG
    Specified dose on specified days

Study Details

The purpose of this study is to evaluate the safety and pharmacokinetics of BMS-986533 in healthy participants receiving single and multiple doses, to assess food and pH effects on the relative bioavailability of BMS-986533, and the P-gp and BCRP-mediated drug-drug interaction potential of the study drug

Key Dates

First listed
Jun 5, 2026
Start date
Jul 13, 2026
Status verified
Jul 2026
Primary completion
Jun 1, 2027
Completion
Jun 1, 2027

Study Design

Enrollment
136 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm A
  • Experimental: Arm B
  • Experimental: Arm C
  • Experimental: Arm D

Primary Outcome Measure

Number of participants with Adverse Events (AE) [ Time Frame: Up to Day 47 ]

Central Contacts

  • BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
    855-907-3286
  • First line of the email MUST contain NCT # and Site #.

Locations (1)

FacilityCityStateZIPSite coordinators
Celerion Coorporate Office NebraskaLincolnNebraska68502
Allen Hunt, Site 0001

Find similar trials in Lincoln, NE

Related Studies